3 results match your criteria: "Anyang Third People's Hospital[Affiliation]"
Eur J Med Res
March 2025
Department of Neurosurgery, Anyang Third People's Hospital, Anyang, 455000, China.
Objectives: To explore the effect of ligustrazine phosphate tablets combined with cerebroside carnosine on neurological function and serum inflammatory factors among patients with ischemic cerebrovascular disease.
Methods: This was a quasi-experimental study. From March 2019 to February 2022, 126 patients were non-randomly divided into control (n = 63) and intervention (n = 63) groups.
Neuroreport
February 2025
Department of Neurology, The People's Hospital of Anyang City, Anyang, Henan Province, China.
Aneurysmal subarachnoid hemorrhage (aSAH) is a life-threatening and life-limiting disease with high mortality and disability rates. Herein, we aim to explore the preventive effect of aminocaproic acid combined with nimodipine on short-term rebleeding in patients with aSAH. Retrospectively, the medical data of patients with aSAH ( n = 256) were collected.
View Article and Find Full Text PDFClin Exp Hypertens
December 2023
Department of Three Wards of Cardiovascular Medicine, Anyang Third People's Hospital, Anyang, China.
Objective: To investigate coronary artery disease (CAD) and its correlation with the ambulatory arterial stiffness index (AASI) in patients with H-type hypertension (essential hypertension combined with hyper-homocysteinemia) and coronary heart disease (CHD).
Methods: Patients with essential hypertension and CHD who were undergoing coronary angiography were enrolled. The general clinical data, biochemical indicators, ambulatory blood pressure monitoring results and coronary angiography results of the selected patients were collected, and the AASI and Gensini scores were calculated.